1. Introduction {#sec1}
===============

Worldwide, 36 million people are estimated to be living with dementia [@bib1]. Cerebral small vessel disease (SVD) causes about 40% of these dementias, alone or in mixed pathologies [@bib2]. SVD also causes a fifth of the 15 million strokes that occur per year worldwide [@bib1]. These three-million SVD (or lacunar) strokes are not severe; so, most lacunar stroke patients survive physically independent, but 36% have mild cognitive impairment or dementia [@bib3]. The frequent cognitive impairment may reflect the association of lacunar stroke with other SVD features [@bib4]. These features (white matter hyperintensities \[WMH\], lacunes, and microbleeds) are typically regarded as clinically "silent" but substantially increase the risk of dementia and stroke individually [@bib5], [@bib6], [@bib7] and combined predict cognitive impairment [@bib8].

Alzheimer\'s disease (AD) and stroke are typically managed and researched separately, but there is substantial evidence of overlap in pathogenesis, for example, dementia expression in life closely reflects the burden of microvascular disease more than of typical AD pathology (amyloid β plaques and neurofibrillary tangles) at postmortem [@bib9], [@bib10], [@bib11]. WMH are common in AD [@bib12]. Management of vascular risk factors [@bib13], lifestyle interventions [@bib14], and stroke prevention [@bib15] could help prevent dementia. However, direct application of vascular prevention strategies that are effective in preventing large artery atherothromboembolic stroke may be ineffective or hazardous if given long term to patients with SVD or AD. Thus, blood pressure reduction and dual antiplatelet drugs failed to prevent cognitive decline or recurrent stroke [@bib16], dual versus single antiplatelet drugs were hazardous after lacunar stroke [@bib17], and antiplatelet drugs increased risk of cerebral hemorrhage in AD [@bib18], reflecting our incomplete understanding of mechanisms underlying SVD and AD [@bib19], [@bib20], and that a different approach is needed [@bib21].

A potential contributor to, or initiator of, the microvascular damage common to both SVD and AD is cerebral microvessel endothelial (or blood-brain barrier \[BBB\]) failure [@bib22], [@bib23], [@bib2]. This could explain the perivascular cell and protein infiltrates, perivascular edema, and secondary axonal and neuronal damage seen pathologically in sporadic SVD [@bib24], [@bib25]. It could also provide a route for entry of amyloid β and inflammatory cells into the brain in AD [@bib26], [@bib27]. Human studies, mostly using cerebrospinal fluid (CSF)/plasma albumin ratio, show that BBB leakage increases subtly with advancing age and is worse in dementia (including AD) than in age-matched controls [@bib28]. The BBB is also more leaky in white and deep gray matter in diabetes-associated mild cognitive impairment [@bib29], in white matter and CSF in lacunar than atherothromboembolic stroke [@bib30], and in white matter in patients with leukoaraiosis [@bib31], vascular [@bib32], and Alzheimer\'s dementias [@bib33], [@bib34]. Recently BBB leakiness was noted to increase in the hippocampus (but not other tissues) with mild cognitive impairment [@bib35].

These studies of BBB function in vivo in patients to date have been small (all *n* \< 50 except 1 [@bib30]) sampled small volumes of brain [@bib35] or used permeability models that ignore aging effects on blood volume and vascular surface area [@bib36], [@bib37] that limit the measurement of permeability accurately. Thus, there is no comprehensive, whole-brain, tissue-specific, in vivo assessment of BBB leakiness in human SVD and none with concurrent independent measures of brain interstitial fluid or tissue damage, making it unclear if BBB leakage is real, pathogenic, or an epiphenomenon in SVD. If pathogenic, then we hypothesized that the leak should worsen with worsening SVD burden, be spatially related to major markers of SVD such as WMH, and be accompanied by increased interstitial fluid. BBB leakage should increase with age, in small vessel (i.e., lacunar) versus atherothromboembolic (i.e., cortical or large artery) ischemic stroke [@bib30] and in hypertension (a major SVD risk factor [@bib38]), and predicts worsening of SVD-associated clinical or imaging features.

We prospectively studied a large cohort of patients with lacunar stroke (a model for vascular effects on neurodegeneration that identifies patients at high risk of cognitive impairment [@bib3]) and cortical ischemic stroke (a control group with similar vascular risk factors [@bib39] and medications), with a range of WMH, followed up at 1 year. We examined the magnitude and spatial distribution of BBB leak and tissue integrity in relation to WMH as a major marker of SVD, using three-dimensional (3D), whole-brain, dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI), diffusion-tensor imaging, T1 mapping, and spatially detailed, tissue-specific analysis.

2. Methods {#sec2}
==========

2.1. Recruitment and eligibility {#sec2.1}
--------------------------------

We recruited patients prospectively who presented with a lacunar or mild cortical ischemic stroke classified clinically using the risk-factor-free Oxfordshire Community Stroke Project classification [@bib40]. We included patients aged ≥18 years, able to consent, within 4 weeks of mild ischemic stroke (i.e., National Institutes of Stroke Scale score \[NIHSS\] ≤5, unlikely to cause physical dependency), with an MR diffusion-weighted imaging (DWI) infarct compatible with the index stroke symptoms ([Fig. 1](#fig1){ref-type="fig"}), or no other cause of symptoms, and no life-threatening illness to preclude 1 year follow-up. We excluded patients who were unable to tolerate MRI or gadolinium-containing intravenous contrast agent.Fig. 1Magnetic resonance brain imaging sequences and processed images. Left, diffusion-weighted image shows recent small deep infarct in the left centrum semiovale (white area) as the index infarct. Top row, left to right, fluid-attenuated inversion recovery and T2-, T2\*-, and T1-weighted axial brain images at the same level as in the large diffusion-weighted image on the left. Bottom row, left to right, colors indicated masking obtained by semiautomated image processing to identify cerebrospinal fluid (yellow), normal-appearing white matter (green), deep gray matter (pink), and white matter hyperintensities (purple); note the index infarct was masked by hand.

2.2. Ethics {#sec2.2}
-----------

Lothian Ethics of Medical Research Committee (REC 09/81,101/54) and NHS Lothian R+D Office (2009/W/NEU/14) approved the study. All patients gave written informed consent.

2.3. Clinical assessments and outcomes {#sec2.3}
--------------------------------------

A specialist stroke physician recorded the medical history and examination including stroke severity (NIHSS, for details, see [Supplementary Material](#appsec1){ref-type="sec"}). A panel of stroke experts assigned the stroke subtype (lacunar or cortical) using the clinical syndrome [@bib40] and acute infarct appearance on DWI MRI. In case of discrepancies, the imaging subtype was used.

We introduced cognitive testing after the study had started and assessed current cognition in as many patients as possible thereafter (Addenbrooke Cognitive Assessment---Revised \[ACE-R\]), premorbid intelligence (National Adult Reading Test \[NART\]), and depression (Beck Depression Index) at 1--3 months after stroke concurrent with BBB imaging (Section 2.4 below).

At 1 year, we assessed all patients for dependency (Oxford Handicap Scale [@bib41], similar to the modified Rankin Scale), recurrent vascular events, cognition (ACE-R), and repeated MRI for WMH burden, new infarcts, or hemorrhages. Patients unable to attend were followed up remotely.

2.4. Neuroimaging {#sec2.4}
-----------------

All MR examinations were performed on one 1.5-T GE Signa HDxt scanner, with tight quality assurance. Diagnostic MR included T1, T2, T2\*, and DTI sequences (see ["Online Methods" and Supplementary Table 1 in Supplementary Material](#appsec1){ref-type="sec"} [@bib42]) to assess infarcts and SVD features [@bib43]. We performed DCE MRI [@bib37] for BBB leak at 1--3 months after stroke (to minimize the index stroke effect on BBB) and T1 mapping for brain water content (see [Supplementary Material](#appsec1){ref-type="sec"}). After two 3D fast-spoiled gradient-echo acquisitions (flip angles 2 and 12°) for precontrast T1 (T~10~) maps, we injected gadoterate meglumine (Gd-DOTA, DOTAREM; Guerbet, Paris, France) 0.2 mL/kg (i.e., 0.1 mmol/kg body weight) at 2 mL/second intravenously via injection pump and then repeated the 3D T1-weighted sequence sequentially 20 times for 24 minutes [@bib44], [@bib36], [@bib37], using long acquisition times to detect subtle BBB leak [@bib36], [@bib35].

2.5. Image processing {#sec2.5}
---------------------

We analyzed all imaging data blind to clinical and other imaging information using validated, qualitative, and quantitative assessments (see ["Online Methods" in Supplementary Material](#appsec1){ref-type="sec"} [@bib42]), as previously [@bib45]. We identified the index infarct and SVD lesions using visual scores (see ["Online Methods" in Supplementary Material](#appsec1){ref-type="sec"}). On coregistered images, we separated CSF, whole-brain, WMH, and normal-appearing white and gray matter [@bib46], [@bib47] ([Fig. 1](#fig1){ref-type="fig"}), differentiating WMH into "more" and "less" intense by degree of abnormality on fluid-attenuated inversion recovery and T2 and T1 sequences. For spatial analysis of BBB leak distribution, we also divided normal-appearing white matter into 10 "contours" each two voxels (≈2 mm) wide from the WMH edge outward (piloted in [@bib48]). We extracted signal intensities from the DCE-MRI pre-post contrast curves per tissue, per voxel, and per time point after intravenous contrast (see ["Online Methods" in Supplementary Material](#appsec1){ref-type="sec"}) [@bib44]. We used sagittal sinus to correct for intravascular contrast [@bib44] as carotid arteries have significant limitations especially in older subjects [@bib37]. We calculated precontrast T1 (longitudinal relaxation time, T~10~ [@bib44], milliseconds) to control for precontrast tissue characteristics [@bib36], [@bib44].

2.6. Sample size {#sec2.6}
----------------

For 80% power, a two-sided test, the estimated sample size was 170 patients to reach 1 year follow-up. Allowing for about 10% dropout required 200 patients to have BBB imaging (see ["Online Methods" in Supplementary Material](#appsec1){ref-type="sec"}).

2.7. Statistical analysis {#sec2.7}
-------------------------

Several mathematical models have been proposed to estimate BBB permeability [@bib36], [@bib37]. The Patlak method best suits low permeability states [@bib36], [@bib49], [@bib50], but all models rely on assumptions regarding capillary surface area that are invalid in low permeability states, for example, that capillary density and blood volume are constant, whereas both vary between tissues and decrease with age and in disease [@bib37]. In the individual tissues and subjects, the actual capillary density is unknown, and it would introduce further potential confounds to use constant values. We explored permeability modeling methods extensively, including in simulations [@bib44], [@bib37], tried to obtain estimates of capillary density to provide realistic factors, but none of these were adequate for use in a wide age range and disease range population such as here. We found strong effects of age on BBB, T1, mean diffusivity (MD), and fractional anisotropy (FA) in separate analyses [@bib47], [@bib48]. Therefore, in our prespecified analysis (see ["Protocol Online" in Supplementary Material](#appsec1){ref-type="sec"}), we did not calculate permeability but used linear mixed modeling of the signal enhancement slopes ([Fig. 2](#fig2){ref-type="fig"}) to identify tissue- and patient-specific differences in BBB leakage. All BBB analyses were adjusted for age, WMH burden, vascular risk factors, intravascular contrast, baseline tissue T1, and time after contrast injection (full statistical details, see ["Online Methods" in Supplementary Material](#appsec1){ref-type="sec"}). Analysis of ACE-R also tested for interactions between lacunar and cortical subtypes. We used SAS 9.3 ([www.sas.com](http://www.sas.com/){#intref0010}) for all analyses and R 2.13.1 for graphs.Fig. 2Change in signal postcontrast in different brain tissues by time averaged across all patients. The graph demonstrates that signal in the blood pool declines after the first pass of bolus but increases progressively in all brain tissues meaning that intravascular contrast does not account for the tissue signal changes. NAWM, normal appearing white matter; WMH, white matter hyperintensities; DGM, deep gray matter; NSL, new (index) stroke lesion; SS, sagittal sinus (represents the blood pool and provides an arterial input function for statistical modeling purposes).

3. Results {#sec3}
==========

We recruited 264 patients ([Supplementary Fig. 1](#appsec1){ref-type="sec"}): 42 declined detailed MRI, 14 were not well enough for BBB imaging, and BBB or structural data were insufficient for analysis in 7, leaving 201 with complete data. The 63 patients without BBB imaging had slightly more severe strokes (median NIHSS 2, interquartile range \[IQR\] 2--4) than the 201 with BBB imaging (NIHSS 2, IQR 1--3, *P* = .03) and were slightly older (66 vs 69 years, *P* = .025), but there were no other differences.

The 92 of 201 (46%) patients with lacunar stroke did not differ significantly from the 109 (54%) with cortical stroke in age (mean: 64, IQR 56--72; 68, IQR 60--76, respectively, *P* = .097) proportion of men, with hypertension, diabetes, or hyperlipidemia ([Supplementary Table 2](#appsec1){ref-type="sec"}). Lacunar strokes were more severe than cortical strokes (NIHSS medians: 1, IQR 0--2; vs 1, IQR 0--1, respectively, *P* = .002), with no difference in time to initial assessment (medians: 3, 1--6; vs 3, 1--8 days, respectively, *P* = .71). Cortical patients had more embolic sources than lacunar (25.7% vs 12%, *P* = .014). Cognitive testing was available for 147 (73%) at 1--3 months (median ACE-R, 90, IQR 83--95) and in 139 (69%) at 1 year (median ACE-R 92, IQR 85--95).

Compared with normal-appearing white matter, BBB leakage was higher in WMH (*P* = .025), CSF (*P* \< .0001), index (*P* \< .0001), and old infarcts (*P* \< .0001) and was lower in deep gray matter (*P* \< .0001, [Supplementary Table 3](#appsec1){ref-type="sec"}, [Fig. 2](#fig2){ref-type="fig"}). BBB leakage increased with ([Table 1](#tbl1){ref-type="table"}) age in all tissues, significantly in deep gray, CSF, and WMH, for example, in deep gray matter by 0.025 × 10^3^ (95% confidence interval \[CI\] 0.0023 × 10^3^, 0.049 × 10^3^, *P* = .030), per 5-year age increment; WMH burden, significantly in all tissues except index or old infarcts, for example, in normal-appearing white matter by 0.024 × 10^3^, (95% CI 0.002 × 10^3^, 0.047 × 10^3^, *P* = .033), per point increase in WMH score; and in index and old infarcts of cortical versus lacunar subtype. BBB leakage was significantly higher in lacunar than cortical subtype in CSF but in cortical than lacunar stroke in normal-appearing white matter and deep gray matter. BBB leakage also increased with ([Table 2](#tbl2){ref-type="table"}): hypertension significantly in all tissues, pulse pressure in some tissues, and with baseline tissue T1 (i.e., water content) in all tissues.Table 1BBB leakage and age, WMH burden (Fazekas score), and stroke subtypeTissueVariableβ coefficient × 10^3^95% CI × 10^3^*P*-valueNormal-appearing white matterAge0.016−0.001, 0.033.065Fazekas score0.0240.002, 0.047.033Stroke subtype−0.110−0.19, −0.030.005Deep gray matterAge0.0250.002, 0.049.031Fazekas score0.0590.028, 0.09.0002Stroke subtype−0.11−0.21, −0.0003.049CSFAge0.2190.158, 0.28\<.0001Fazekas score0.2050.124, 0.287\<.0001Stroke subtype0.3630.082, 0.644.011WMHAge0.0590.035, 0.082\<.0001Fazekas score0.1040.072, 0.136\<.0001Stroke subtype−0.040−0.150, 0.068.46Index infarctAge0.0450.001, 0.089.045Fazekas score0.017−0.040, 0.075.57Stroke subtype−0.520−0.720, −0.330\<.0001Old infarctAge0.049−0.0015, 0.10.057Fazekas score0.041−0.030, 0.11.24Stroke subtype−0.430−0.680, −0.190.0004[^1][^2]Table 2Association between BBB leakage, vascular risk factors, and brain parameters: hypertension, mean arterial pressure, smoker status, brain tissue T1 signal precontrast, and intravascular signal (sagittal sinus), adjusted for one another, age, and combined Fazekas scoreTissueVariableβ coefficient × 10^3^95% CI × 10^3^*P*-valueNormal-appearing white matterHypertension0.2060.118, 0.295\<.0001Mean arterial pressure−0.00105−0.0036, 0.0015.41Pulse pressure0.00121−0.00061, 0.0030.19Smoking status−0.050−0.130, 0.026.18Tissue T10.460.153, 0.768.0033Intravascular contrast0.050−0.080, 0.181.45Deep gray matterHypertension0.2330.111, 0.354.0002Mean arterial pressure0.00017−0.0033, 0.0036.93Pulse pressure0.003800.0013, 0.0063.003Smoking status0.035−0.080, 0.146.53Tissue T10.365−0.0018, 0.732.051Intravascular contrast0.00062−0.180, 0.182.99CSFHypertension0.3380.016, 0.66.040Mean arterial pressure0.0160.0064, 0.025.0009Pulse pressure0.0170.011, 0.024\<.0001Smoking status−0.30−0.590, −0.010.042Tissue T11.1070.903, 1.31\<.0001Intravascular contrast1.3630.878, 1.848\<.0001WMHHypertension0.2560.131, 0.38\<.0001Mean arterial pressure0.000368−0.0032, 0.0039.84Pulse pressure0.003330.00076, 0.00589.011Smoking status−0.110−0.23, 0.0002.050Tissue T10.5360.163, 0.909.0049Intravascular contrast0.2370.052, 0.423.012Index infarctHypertension0.6770.444, 0.91\<.0001Mean arterial pressure−0.00298−0.009, 0.003.35Pulse pressure−0.00203−0.0066, 0.0025.38Smoking status−0.040−0.240, 0.154.67Tissue T11.6171.249, 1.984\<.0001Intravascular contrast−0.040−0.390, 0.305.81Old infarctHypertension0.4720.208, 0.735.0005Mean arterial pressure0.0160.007, 0.024.0002Pulse pressure0.00261−0.0033, 0.0085.39Smoking status−0.40−0.64, −0.16.001Tissue T10.7730.317, 1.228.001Intravascular contrast0.086−0.330, 0.499.68[^3]

Analysis of spatial distribution of BBB leakage in normal-appearing white matter ([Fig. 3](#fig3){ref-type="fig"}) showed that BBB leakage increased linearly at 0.0099 × 10^3^ (95% CI 0.0114 × 10^3^, 0.0084 × 10^3^, *P* \< .0001) per contour closer to the WMH edge, adjusted for age, Fazekas score, blood pressure, stroke subtype, and smoking. The leak was worst in the WMH where it was worst in the most abnormal areas ("intense" versus "less intense" WMH). Additionally, MD increased from the 4 mm contour and T1 from the 2 mm contour proximate to the WMH edge; both were yet higher in less intense and highest in intense WMH ([Fig. 3](#fig3){ref-type="fig"}), consistent with an increase in interstitial water mobility and then in measureable interstitial water close to the WMH, with the most abnormal values in the WMH. Axonal integrity (FA) decreased with increasing proximity to WMH, being lowest in the most intense WMH, consistent with most axonal disruption being in the most abnormal-looking tissue.Fig. 3Representative axial brain magnetic resonance imaging (left, same case as in [Fig. 1](#fig1){ref-type="fig"}) showing white matter hyperintensities and contours at two voxel increments (approximately 2 mm width) extending concentrically into the normal-appearing white matter from which blood-brain barrier leakage (Pby, graph top left), mean diffusivity (graph top right, ×10^−9^ mm^2^/s), fractional anisotropy (graph bottom left), and T1 (graph bottom right, ms) were extracted. White matter hyperintensities are split into intense and less intense to determine the difference in these biomarkers by severity of white matter hyperintensities and by all white matter hyperintensities, as indicated on the x-axis. WMH, white matter hyperintensities; FA, fractional anisotropy; iWMH, intense white matter hyperintensities; liWMH, less intense white matter hyperintensities.

On further assessing the contours by Fazekas WMH score corrected for age ([Fig. 4](#fig4){ref-type="fig"}), patients with most WMH (Fazekas score 5--6) had the highest BBB leakage, water content (MD, T1), and lowest axonal integrity (FA) in normal-appearing white matter and WMH (for details, see [Supplementary Fig. 2](#appsec1){ref-type="sec"}).Fig. 4Changes in blood-brain barrier leakage (top left, Pby), mean diffusivity (top right, ×10^−9^ mm^2^/s), fractional anisotropy (bottom left), and T1 (bottom right, ms) in white matter hyperintensities and 2 mm incremental contours expanding concentrically across normal-appearing white matter, according to white matter hyperintensities burden categorized by Fazekas score into low (0--2), medium (3--4), and high (5--6) white matter hyperintensities burden. Contours as in [Fig. 3](#fig3){ref-type="fig"}, left-hand image. [Supplementary Fig. 3](#appsec1){ref-type="sec"} shows these data by individual Fazekas white matter hyperintensities scores. Data are age adjusted. Faz_group, Fazekas score group; WMH, white matter hyperintensities; MD, mean diffusivity; iWMH, intense white matter hyperintensities; LiWMH, less intense white matter hyperintensities; FA, fractional anisotropy.

At 1--3 months after stroke, ACE-R was associated negatively with age and positively with premorbid intelligence (NART), but not with WMH score or concurrent BBB leakage in any tissues, with no difference between lacunar and cortical stroke patients ([Supplementary Table 4](#appsec1){ref-type="sec"}). At 1 year, BBB leakage in WMH predicted lower ACE-R in lacunar (β −3.52, 95% CI −5.9, −1.13) but not cortical (β 0.03, 95% CI −5.77, 5.12) stroke patients; high WMH score and NART, but not age, predicted ACE-R in both stroke subtypes ([Supplementary Table 5](#appsec1){ref-type="sec"}). Incorporating ACE-R at 1--3 months after stroke into the 1-year ACE-R prediction model (to assess change in ACE-R and BBB leak) showed that BBB leakage in WMH predicted a decline in ACE-R at 1 year in both lacunar and cortical stroke patients (β −1.89, 95% CI −3.62, −0.16). ACE-R and NART at 1--3 months also predicted decline in ACE-R at 1 year ([Supplementary Table 6](#appsec1){ref-type="sec"}) but not WMH score, hypertension, or age.

At 1 year, 21 patients had a clinically evident recurrent stroke, 19 had a new infarct on MRI (21 of 201 could not have repeat scanning, [Supplementary Fig. 1](#appsec1){ref-type="sec"}), and 34 patients were dependent or dead (17%). WMH burden was the strongest predictor of recurrent stroke or dependency, overwhelming BBB associations except for BBB leakage in CSF that showed a weak association with dependency ([Supplementary Table 7](#appsec1){ref-type="sec"}). Vascular risk factors did not predict outcome.

4. Discussion {#sec4}
=============

We show, in this large stratified patient cohort, that subtle increases in BBB leakage appear to be widespread in normal-appearing white matter and more pronounced in WMH, increasing with the visible severity of tissue damage. The BBB leak is accompanied by increased interstitial water mobility and water content close to and in the WMH, providing support for the BBB leak findings. BBB leakage in normal-appearing white matter and in WMH was worst in patients with severe WMH, with hypertension and increased pulse pressure. BBB leakage in WMH predicted cognitive impairment at 1 year in lacunar stroke and cognitive decline between 1 and 3 months and 1 year after stroke in both lacunar and cortical stroke patients. Taken together, these observations suggest that BBB leakage precedes increases in interstitial fluid and axonal damage, all which worsen as WMH worsen; BBB leak in WMH also predicts cognitive decline at 1 year, particularly in lacunar stroke patients who are already known to be at high risk of cognitive decline after stroke [@bib3]. We show that WMH associate with BBB leakage regardless of the underlying stroke subtype, findings that are generalizable to older subjects with WMH. Thus, BBB leakage appears to be important in pathogenesis of SVD-associated brain damage in large clinical populations. The association between BBB leak, hypertension, and pulse pressure provides a mechanism whereby hypertension may worsen WMH [@bib38] and thus may contribute to declining cognition. Pathogenesis involving BBB leak may also explain the apparent lack of benefit for antithrombotic drugs and increased hemorrhage risk in SVD [@bib17], [@bib51] and AD [@bib18].

We provide conclusive in vivo evidence that normal-appearing white matter, in the presence of WMH, is not normal, at any adult age, but increasingly abnormal with increasing WMH burden [@bib48], [@bib47] and by proximity to WMH [@bib52], [@bib53]. In comparison with recent work [@bib52], our study provides more extensive spatial sampling of brain white matter and multiple independent imaging parameters. We show, in this much larger sample, that subtle BBB failure can be detected with DCE MRI in large clinical studies. In comparison with recent work [@bib35], our study provides full brain coverage, volumetric analysis of BBB leakage across spatially related tissue while preserving sensitivity to low-grade BBB leak [@bib37], a large, highly phenotyped, clinically relevant patient sample, and assumption-free statistical analysis. This approach was based on extensive testing of models including simulated data which made it clear that current models were not suitable for low permeability states across a wide range of age and disease [@bib37]. The differences in BBB leakage in index and old infarcts demonstrate the sensitivity of this method to detect BBB leakage.

Why should increased BBB leakage occur in SVD and is this also relevant to AD? AD and SVD pathologies commonly co-occur, cognition is worse when SVD is present in AD [@bib12], vascular risk factors accelerate both disorders, both are associated with elevated systemic inflammatory markers, and microglial activation is common in both diseases pathologically. The BBB has a huge surface area, handles a fifth of the cardiac output at rest, and maintains the correct brain interstitial milieu within tight limits for normal brain function, a major physiological challenge [@bib2]. A slight decline in barrier function could result in vascular wall and perivascular parenchymal damage from fluid shifts [@bib54] or allow neurotoxins such as serum amyloid P, an important precursor to amyloid deposition [@bib27], into the brain. The findings are consistent with BBB failure being an early pathogenic step in SVD, with axonal loss occurring secondarily [@bib54], [@bib20]. BBB integrity declines with normal aging and is worse in AD according to biochemical [@bib28] and pathological [@bib33] analyses. BBB failure may occur through multiple factors, for example, hypertension, diabetes, inflammation [@bib24], smoking, and increased sodium intake [@bib50], all damage the vascular endothelium. Cerebral blood flow is reduced in both SVD and AD: hypoperfusion triggers BBB failure in experimental models, and fibrinogen leakage across the BBB was associated with astrocyte morphological changes, reversal of aquaporin 4 distribution on end feet implying glyovascular malfunction, and irreversible damage in WMH seen at postmortem in patients with cognitive impairment after stroke in life [@bib55]. WMH heritability [@bib56] and genetics [@bib57] suggest that some individuals may be more susceptible to damage in the neurovascular unit, including the BBB [@bib58], perhaps accounting for variation in SVD-related brain damage and clinical expression between individuals with apparently similar risk factor exposures.

Our results provide evidence that BBB leakage is an important, likely early pathological event in development of SVD-associated brain damage. WMH should sound alarm bells to identify potentially modifiable risk factors at all ages and in all dementias. Brain interstitial fluid shifts are potentially remediable, at least initially: reduction in interstitial fluid, for example, by improved endothelial function and reduced BBB leak, might prevent accumulation of permanent brain injury, slowing neurodegeneration, preserving cognition, and preventing dementia and stroke. Persistent BBB malfunction may precipitate worsening of microvessel wall injury, with secondary inflammation [@bib24], impaired vasoreactivity [@bib59], or luminal narrowing and hence tissue ischemia---a vicious cycle of brain damage. Future research should target ways to reduce small vessel endothelial damage to prevent progressive BBB breakdown and brain injury including, but not restricted to, improved management of lifestyle factors (e.g., exercise [@bib14], diet [@bib50]) and vascular risk factors (e.g., hypertension).Research in Context1.Systematic review: We reviewed the literature on blood-brain barrier (BBB) leakage detected with magnetic resonance imaging in humans during aging, in small vessel disease (SVD) or dementia, from multiple electronic bibliographic databases and identified six studies (*n* = 203).2.Interpretation: Our study doubles the available data on BBB leakage and provides independent evidence on the hypothesis that BBB leakage is pathogenic in SVD-related brain damage including tissue fluid measures, spatial distribution, two SVD markers, age, disease burden, risk factor (hypertension), and cognition associations.3.Future directions: Our results provide a testable hypothesis, a route for amyloid entry to the brain, and should encourage new thinking about SVD and/or aging-related brain damage and cognitive decline beyond ischemia or amyloid deposition. Future research should focus on the many lifestyle and risk factor--modifying interventions that could protect the cerebrovascular endothelium and developing new specific drugs to preserve or enhance BBB function.

Supplementary data {#appsec1}
==================
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[^1]: Abbreviations: BBB, blood-brain barrier; WMH, white matter hyperintensities; CI, confidence interval; CSF, cerebrospinal fluid.

[^2]: NOTE. Values are BBB leakage (change in postcontrast signal per minute) per 5-year increase in age, per point increase in Fazekas score, or lacunar versus cortical stroke. The interaction coefficients for age, Fazekas score, and subtype are derived from three separate models (the data were already adjusted for key predictors listed previously and simultaneous fitting of multiple interaction terms was not supported). Age, Fazekas score, and stroke subtype are each adjusted for each other and sagittal sinus signal, brain tissue signal precontrast (T~10~), mean arterial blood pressure, diagnosis of hypertension, pulse pressure, and smoker status. In stroke subtype, a negative effect estimate indicates that values are lower in patients with lacunar than with cortical stroke. A higher Fazekas score indicates more WMH.

[^3]: Abbreviations: BBB, blood-brain barrier; CI, confidence interval; CSF, cerebrospinal fluid; WMH, white matter hyperintensities.
